Lepu Biopharma (2157) Fundamentals 2026 — P/E 29.1x, Revenue Analysis | SniperIQ
Lepu Biopharma (2157) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK$8.8B, trading at HK$4.86 on the HKSE. This SniperIQ fundamentals page covers Lepu Biopharma's valuation (P/E 29.1x, P/B 5.5x), profitability (net margin 27.8%), revenue (¥911M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Lepu Biopharma's market cap?
Lepu Biopharma (2157) has a market capitalization of approximately HK$8.8B, trading at HK$4.86 on the HKSE. Market cap moves with the live share price.
What is Lepu Biopharma's P/E ratio?
Lepu Biopharma's trailing twelve-month P/E ratio is 29.1x, with a price-to-book (P/B) of 5.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Lepu Biopharma?
Lepu Biopharma runs a net profit margin of 27.8%, a gross margin of 85.5%, and an operating margin of 5.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Lepu Biopharma generate?
Lepu Biopharma reported revenue of ¥911M for fiscal year 2025, with net income of ¥255M and earnings per share (EPS) of 0.14. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Lepu Biopharma pay a dividend?
Lepu Biopharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Lepu Biopharma financially healthy?
Lepu Biopharma carries a debt-to-equity ratio of 0.76x and a current ratio of 0.98x, with a market beta of -0.43. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Lepu Biopharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Lepu Biopharma (2157) the key facts are: market cap HK$8.8B, P/E 29.1x, revenue ¥911M, 52-week range 3.55-10.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Lepu Biopharma's full fundamentals live
Get Lepu Biopharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.